**Marquette University**

**e-Publications@Marquette**

***Dentistry Faculty Research and Publications/School of Dentistry***

***This paper is NOT THE PUBLISHED VERSION*.**

Access the published version via the link in the citation below.

*Journal of Biomedical Materials Research, Part A*, Vol. 108, No. 6 (June 2020): 1338-1350. [DOI](https://doi.org/10.1002/jbm.a.36906). This article is © Wiley and permission has been granted for this version to appear in [e-Publications@Marquette](http://epublications.marquette.edu/). Wiley does not grant permission for this article to be further copied/distributed or hosted elsewhere without the express permission from Wiley.

In Vitro And In Vivo Effects of Concentrated Growth Factor on Cells And Tissues

Fahimeh Tabatabaei

Dental Research Center, Research Institute of Dental Sciences, Department of Dental Biomaterials, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran

School of Dentistry, Marquette University, Milwaukee, Wisconsin, USA

Zahra Aghamohammadi

Dental Research Center, Research Institute of Dental Sciences, Department of Dental Biomaterials, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Lobat Tayebi

School of Dentistry, Marquette University, Milwaukee, Wisconsin, USA

# Abstract

This article reviews the biological outcome of the concentrated growth factor (CGF), a new platelet derivative used for tissue regeneration, in published articles related to the use of this product in basic and clinical studies. An electronic literature research using PubMed and SCOPUS was performed using combination of keywords: “concentrated growth factor” (OR “CGF”), AND “stem cells,” AND “cells” OR “cell proliferation” OR “cell migration” OR “cell differentiation,” AND “repair” OR “survival” OR “revitalization,” AND “tissue” OR “bone.” Forty-five articles that were published between 2012 and 2020 met the inclusion criteria. These studies have used CGF as fresh solid form, freeze-dried, membrane, extract, or exudate. Most studies demonstrate the positive effects of CGF in a dose-dependent manner under certain concentrations. Studies comparing CGF with other platelet concentrates, report lower efficiency, no statistically significant differences, or better results for CGF. Combination of CGF with stem cells and biomaterials significantly improves bone regeneration and the effect of allograft or collagen membrane is better than CGF alone. For a better examination of the biological outcomes of CGF, the standardization of CGF preparation regarding the choice of the test tube material for blood collection, the required volume of blood, the necessary count of platelets in CGF, and the most appropriate type of CGF are recommended.

# 1 INTRODUCTION

Tissue engineering and regenerative medicine requiring stem cells, scaffolds, and growth factors are developing fast. In this development, the product cost, the processing time, the similarity with natural tissues, degradation of materials, and ethical issues are the most important considerations. Using stem cells is now shifting to stem cell-free concept by the administration of stem cell-derived exosomes or conditioned media (Kusuma, Carthew, Lim, & Frith, **2017**; Phinney & Pittenger, **2017**). New approaches in scaffolds consist of additive manufacturing (3D printing), decellularizing and scaffold-less strategies like self-assembling, self-organizing, and 3D bioprinting (Tatullo, Codispoti, Paduano, Nuzzolese, & Makeeva, **2019**; Thomas et al., **2016**). With great roles of growth factor in cell recruitment, proliferation, differentiation, and tissue repair, new strategic approaches to growth factors delivery are established (Mitchell, Briquez, Hubbell, & Cochran, **2016**; Nyberg, Holmes, Witham, & Grayson, **2016**). The release of growth factors is one of the challenging issues in tissue regeneration. Currently, platelet concentrates—like platelet-rich plasma (PRP), platelet-rich fibrin (PRF) and CGF—as a reservoir of growth factors that can control their release are under many investigations (Kang et al., **2011**). PRP and plasma rich in growth factors (PRGF), as the first generation of these products, have been used in several clinical fields. However, the addition of anticoagulated agents and thrombin or calcium chloride for induction of fibrin polymerization leads to some debate about its biosafety. To overcome these drawbacks, PRF, which is the second generation of platelet concentrates, self-clotted, and set by one-step centrifugation, was presented (Raghoebar et al., **2005**). Many studies have proven the beneficial effects of L-PRF (with high number of leukocytes) and A-PRF (prepared by centrifugation at lower speed than L-PRF) in tissues regeneration (Bakhtiar et al., **2017**). Finally, repeated switch of the centrifugation speed resulted in the presentation of CGF as a modified form of PRF, with high amount of cytokines and very stiff texture, by Sacco (Masuki et al., **2016**; Qiao & An, **2017**).

Intrinsic coagulation reaction in venous blood causes activation of CGF, which contains many different growth factors like vascular endothelial growth factor (VEGF), transforming growth factor beta 1 (TGF-β), and platelet-derived growth factor (PDGF). The effects of these growth factors on tissue regeneration are approved in many studies. Also, the release of chemokines responsible for cell recruitment is another advantage of this new generation of platelets concentrates. The dense network of CGF leads to the protection of growth factors and chemokines (Lundquist, Dziegiel, & Agren, **2008**). Special centrifuge (Medifuge, Silfradent srl, Italy) used for extraction of CGF is the same device used for PRF isolation, but unlike constant speed for PRF, it utilizes altered speed rate. The process is easy and results in a denser matrix, which has more growth factors than PRP and PRF and potentially better sustained release of growth factors as a drug delivery system (Sohn et al., **2011**). Besides platelets, the presence of CD34-positive stem cells in CGF has been established in one study (Rodella et al., **2011**). Moreover, a study on the release pattern of CGF in scaffolds, like deproteinized bovine bone mineral and intrafibrillar-mineralized collagen (IMC), showed that mixture of CGF with IMC causes a sustained release of growth factors and cytokines until 28 days (Yu, Wang, Liu, & Qiao, **2019**). It seems that addition of some biomaterials—like beta-tricalcium phosphate (β-TCP)—could enhance the release of some growth factors, like bone morphogenetic protein (BMP) 2 and 7, which have an important role in bone regeneration (Bonazza et al., **2018**).

In recent years, applications of autogenous growth factors prepared from centrifugation of whole blood increased in wound healing and tissue regeneration. These platelet concentrates can be used alone or in combination with other biomaterials for soft tissue healing or bone formation. Utilization of these growth factors in many clinical issues like ridge preservation and augmentation, sinus lift procedures, fracture repair, and implant stability has been reported (Mirkovic, Djurdjevic-Mirkovic, & Pugkar, **2015**; Pirpir, Yilmaz, Candirli, & Balaban, **2017**; Shyu, Fu, & Shen, **2016**). Avoiding immunoreactions, cross-contamination, and ethical concerns make CGF a very popular product, among all platelet concentrates, for tissue repair (Zhang & Ai, **2019**). Many clinical studies actually focus on the effects of CGF in bone regeneration (Brignardello-Petersen, **2020**; Doan, Reher, Duong, Wang, & Truong, **2019**; Özveri Koyuncu, Işık, Özden Yüce, Günbay, & Günbay, **2019**; Xu, Qiu, et al., **2019**). With the increasing use of CGF, questions about its FDA approval are raised. According to FDA's 21 CFR 1271 of the Code of Regulations, FDA's traditional regulatory pathway is not required for blood products; however, the device used for their preparation will need FDA clearance. Harvest SmartPrep Platelet Concentrate System (Harvest Technologies, Plymouth, MA) and the 3i Platelet Concentrate Collection System (3i Implant Innovations, Palm Beach Gardens, FL, United States) for preparing PRP, and IntraSpin L-PRF (Intra-Lock Inc., Boca Raton, FL) for preparing L-PRF, have FDA clearance (Agrawal, **2017**; Dohan Ehrenfest et al., **2014**). Off-label use of other devices is not restricted but requires high responsibility of clinicians and their awareness about the advantages and disadvantages of CGF application (Beitzel et al., **2015**; Jones, Togashi, & Thomas Vangsness Jr., **2018**).

Published articles about the clinical and biotechnological application of CGF have increased; however, no review article summarizes the results. Our objective was to review the in vitro and in vivo biological effects of CGFs.

# 2 METHODS

A comprehensive search in PubMed and SCOPUS was carried out using keywords: “concentrated growth factor” (OR “CGF”), AND “stem cells,” AND “cells” OR “cell proliferation” OR “cell migration” OR “cell differentiation,” AND “repair” OR “survival” OR “revitalization,” AND “tissue” OR “bone.” Correspondingly, references of founded articles were investigated to find other relevant articles. Only publications in the English language were considered for evaluation and extraction of data. Articles published from 2000 to 2020 were assessed based on our research question, which was addressed respecting *PICOS* elements (**P**—participants or population, **I**—intervention, **C**—comparison, control or comparator, **O**—outcome, and **S**—study design) (Table **1**). Case reports and articles not considering the control group were removed from our study. The full texts of all corresponding articles were assessed and finally, 45 studies were selected for this review.

**Table 1.**PICOS format of our reviews' question

|  |  |
| --- | --- |
| **Component** | **Description** |
| Population | Studies using CGF and considering its effect on cells or tissues |
| Intervention | Using CGF for cell proliferation, cell differentiation, or healing damaged tissues |
| Comparison | Control group with no treatment or receiving other treatments |
| Outcome | Cell behavior or tissue response after treatment |
| Study design | In vitro and in vivo studies |

Abbreviations: CGF, concentrated growth factor; PICOS, **P**—participants or population, **I**—intervention, **C**—comparison, control or comparator, **O**—outcome and **S**—study design.


# 3 RESULTS

## 3.1 Methods of CGF preparation and application

CGF is applied as prepared (solid form), or as membrane, exudate or conditioned media. For preparing the solid form, venous blood is drowned into sterile VACUETTE tubes with a glass surface. There is no need for using synthetic or catalytic agents during the processing of CGF. Tubes are centrifuged using the built-in program (30 s acceleration, 2 min at 408 × *g*, 4 min at 323 × *g*, 4 min at 408 × *g*, 3 min at 503 × *g*, and 36 s deceleration and stop). Then, the intermediate gel layer in the final three-layered product, which is CGF, should be separated from the third layer by scissor, and could be used as prepared or freeze-dried (Borsani et al., **2018**).

For producing the CGF membrane, the fresh form of CGF will be compressed for 1 or 2 min. The release of growth factors in the resulting film is slower than the solid form (Qiao & An, **2017**). The fluid isolated from CGF clot during pressing and collected in the tray of the endo box is named CGF exudate (CGFe). The next step is centrifugation of this exudate at 500 × *g* for 5 min and removal of red blood cells (Li et al., **2019**). CGFe could also be prepared by mincing CGF clots, homogenizing it and storing at −80°C for 1 hr, then using the supernatants after centrifugation (Jun, Lei, Qifang, Yuan, & Deqin, **2018**).

CGF extract or conditioned media is another form of CGF used in research. By placing CGF fresh membranes or lyophilized membrane in culture medium (5–10 ml) for one or several days (7–14 days) and centrifuging the media, the supernatant could be used as CGF extract or CGF-conditioned medium (CCM). CCM should be supplemented with fetal bovine serum and antibiotics (Hong, Li, Cai, & Jiang, **2019**; Jin et al., **2018**). Another way to produce CGF extract is placing the CGF membrane into a sterile insert above the seeded cells in the six-well plates (an insert in each well), which are immersed in culture medium (for 72 hr) (Borsani et al., **2015**). Figure **1** shows different steps in preparing the various types of CGF.

[](https://onlinelibrary.wiley.com/cms/asset/01e08fbb-77ff-422f-94f7-d29a3059c6b5/jbma36906-fig-0001-m.jpg)

**Figure 1** Steps in preparing the various types of concentrated growth factor (CGF)

One more type of applied CGF is its mixture with biomaterials or autologous bone. For this purpose, fresh CGF will be cut into small fragments and mixed with biomaterial at a defined volume ratio. The result of the mechanical mixture is an adhesive paste that can be placed in tissue defect (Qiao, Duan, Zhang, Chu, & Sun, **2016**).

## 3.2 Effect of CGF on stem cells

Stem cells were used in 11 studies to evaluate their proliferation and differentiation under treatment with various types of CGF (Table **2**). Different types of stem cells, which were derived from PDL, dental pulp, apical papilla, bone marrow, adipose tissue, and gingiva have been used in these studies. Considering the high amount of TGF-β, IGF, VEGF, and PDGF in CGF and their important effect on proliferation and differentiation (Borsani et al., **2015**), these characters were evaluated in almost all studies. Most of these studies reported more proliferation in a dose-dependent manner. However, four studies showed that a high dose of CGF does not have a positive effect. In the study of Honda et al., concentrations of 1–10% of CGF extract had a positive effect on proliferation and differentiation in a dose-dependent manner, while high concentration (20%) had an inhibitory effect (Honda et al., **2013**). Chen et al., by studying the effect of 5, 10, 20, and 40% CGF, demonstrated more proliferation and differentiation in 10% CGF (Chen et al., **2018**). No dose-dependent effect was also stated by Hong et al. in investigation of the effect of three different concentration of CGF–CCM (1, ½, ¼) (Hong et al., **2019**). Likewise, Qiao et al. reported lower cell proliferation by using five CGFs (5 ml whole blood) in comparison to three CGFs (3 ml whole blood) (Qiao & An, **2017**). Although under treatment with CGF extracts, higher cells proliferation in a dose-dependent manner was approved by Jin et al., enhanced cell migration, and differentiation in the low doses (<50%) of CGF was noticeable (Jin et al., **2018**). Two studies compared effect of CGF with PRF, and the results show that PRF is more efficient in osteogenic differentiation of stem cells, while CGF is more efficient in vascular differentiation (Hong et al., **2018**; Hu et al., **2018**).

**Table 2.**List of studies on the effects of CGF on stem cells

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Stem cell** | **Intervention** | **Control group** | **Features tested** | **Assays** | **Outcome** |
| Honda, Tamai, Naka, Yoshikawa, and Myoui (2013) | hTERTE6/E7 human MSCs | CGF extract, at concentrations of 1, 3, 5, 10, or 20% | Medium without CGF | Proliferation, differentiation | Cell count, ALP staining and activity, Alizarin Red, and Von Kossa staining, qRT-PCR | More proliferation, and differentiation of hTERTE6/E7 human MSCs in a dose dependent at concentrations between 1 and 10%, inhibitory effect at higher concentrations |
| Yu and Wang (2014) | Beagle PDLSCs | One CGFs (prepared with 1 ml fresh whole blood), three CGFs (3 ml whole blood), osteogenesis-induced fluid +1 CGF, osteogenesis-induced fluid +3 CGFs | The standard group (0 CGF), osteogenesis-induced fluid (0 CGFs) | Proliferation, osteogenic differentiation | Cell counting, MTT assay, Alizarin Red S staining, ALP activity, qPCR, western blot analysis, immunohistochemistry | More proliferation and differentiation by using CGF in a dose-dependent manner |
| Qiao and An (2017) | hPDLCs | One CGF (1 ml whole blood), three CGFs (3 ml whole blood), five CGFs (5 ml whole blood) | Negative control group (standard cell culture), positive control group (standard cell culture +40 ng/ml rhPDGF-AB 100 ng/ml rhTGF-β1) | Proliferation, ALP activity, Wnt3a expression | MTT assay, p-NPP assay, qRT-PCR | More proliferation and ALP activity and more Wnt3a mRNA expression in a dose dependent Manner in groups treated by CGFs. Optimal concentration: three CGFs |
| Hong, Chen, and Jiang (2018) | SCAPs | Freeze-dried CGF–CCM | PRF-CCM and normal medium | Proliferation, migration, mineralization and differentiation | Cell counting Kit-8, Transwell assays, Alizarin Red S staining qPCR | More proliferation, migration and mineralization in PRF and CGF groups than normal medium, more differentiation in PRF group |
| Jin et al. (2018) | DPSCs | Different concentrations (5, 10, 20, 50, or 80%) of CGF extracts | Blank DMEM | Proliferation, EdU assay, migration, odontoblastic differentiation, endothelial differentiation | Cell counting Kit-8, scratches, ALP assay, Alizarin Red S staining, qRT-PCR and western blot, tube formation assay | Higher cell proliferation in a dose-dependent manner. More migration, and differentiation in low doses (<50%) of CGF |
| Hong et al. (2019) | SCAPs | CGF–CCM in three different concentrations (1, ½, ¼) | Normal medium | Proliferation, migration, mineralized nodule formation and odontoblastic differentiation | Cell counting kit-8, Transwell Filter Inserts, Alizarin red staining, RT-qPCR | More proliferation, migration, and differentiation under treatment with CGF. No dose-dependent effect |
| Chen et al. (2018) | BMSCs | 5, 10, 20, and 40% CGF | DMEM, osteogenesis induction medium | Proliferation, mineralization, osteogenic differentiation | CCK-8 assay, ALP-positive cell staining and mineralized nodule formation assay, RT-qPCR analysis and western blotting | More proliferation in 10% CGF. Better differentiation in this group than positive control |
| Hu, Jiang, Wang, Tian, and Wang (2018) | hADSCs | 1 ml of CGF | Culture medium, 1 ml of PRP, 1 ml of PRF | Proliferation and vascular differentiation | Cell count, RT-PCR | Higher cell proliferation and expression of VEGF and PECAM in CGF group than other groups |
| Li et al. (2019) | hPDLCs stimulated by TNF-α | CGFe (concentration 50%) or CGFe + TNF-α | Culture medium, TNF-α (10 ng/ml) treatment | Proliferation, osteogenic differentiation | Cell counting Kit-8 assays, Alizarin Red S staining, ALP activity, western blotting, and qPCR | More proliferation and differentiation in CGFe groups, even in the presence of TNF-α-induced inflammation |
| Xu, Qiao, et al. (2019) | hDPSCs | CCM extracted by freeze-dried method | Cell treated with or without LPS | Proliferation, migration, differentiation | CCK-8, Transwell assays, Alizarin Red staining, ALP activity, qPCR, HE | Positive effect of CGF on the proliferation, migration, and differentiation of hDPSCs exposed to LPS |
| Chen, Chen, et al. (2019) | GMSCs | CGF extract: 5, 10, 20, and 40% | DMEM; osteogenesis induction medium | Cell proliferation, mineralization, differentiation | MTT, CCK-8 assay. ALP staining, RT-qPCR, western blotting | Proliferation and osteogenic differentiation of GMSCs treated with CGF |

Abbreviations: ALP, alkaline phosphatase; BMSCs, bone marrow-derived mesenchymal stem cells; CCK, cell counting kit; CCM, conditioned medium; CGFe, concentrated growth factor exudate; DMEM, Dulbecco's modified Eagle medium; DPSCs, dental pulp stem cells; GMSCs, gingiva-derived mesenchymal stem cells; hADSCs, human adipose-derived stem cells; HE, hematoxylin and eosin stain; hPDLCs, human periodontal ligament cells; LPS, lipopolysaccharides; MSCs, mesenchymal stem cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; PECAM, platelet endothelial cell adhesion molecule; pNPP, *p*-nitrophenyl phosphate; PRF, platelet-rich fibrin; RT-qPCR, quantitative reverse transcription polymerase chain reaction; SCAPs, human stem cells of the apical papilla; TNF-α, tumor necrosis factor; VEGF, vascular endothelial growth factor.

**Table 3.**List of studies on the effects of CGF on adult cells or cell lines

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Cell** | **Intervention** | **Control group** | **Features tested** | **Assays** | **Outcome** |
| Borsani et al. (2015) | Three different types of human cell lines: NHDF, HUVEC, HOB | Basal medium + CGF, growth medium + CGF | Basal medium, growth medium | Proliferation | FACS | Higher proliferation in growth medium + CGF |
| Takeda, Katsutoshi, Matsuzaka, and Inoue (2015) | Rat bone marrow cells | CGF from rat blood | PPP gel | Morphology, proliferation, differentiation | Immunofluorescence, WST-1 assay, ALP activity | More proliferation and differentiation in CGF-coated disks |
| Masuki et al. (2016) | Human alveolar bone-derived periosteal cells | CGF extract | PRP, PRGF, A-PRF extract | Proliferation | Photographed and counted in three randomly selected views using image-PRO plus software | More proliferation in PRP > CGF > A-PRF > PRGF |
| Qin, Wang, Sun, et al. (2016) | SCs | CGF extract from rats | DMEM | Proliferation, cell cycle analysis, expression of NGF and GDNF | CCK-8 assay, flow cytometry, RT-qPCR, Western blot | More proliferation and secretion of neurotrophic factors in CGF-treated SC |
| Qin, Wang, Zheng, et al. (2016) | SCs | CGF extract from rats | DMEM | Migration, expression of integrin β1 | Scratch wound-healing assay, Western blot, integrin β1 gene silencing, RT-qPCR | More migration in CGF group through higher expression of integrin β1 |
| Borsani et al. (2018) | Human osteoblasts treated with bisphosphonates | CGF, CGF + RSV 10, CGF + AL 5, CGF + ZOL 5, CGF + AL 5 + RSV 10, CGF + ZOL 5 + RSV 10 | Complete medium *(OGM)*—Control OGM + RSV 10, OGM + AL 5, OGM + ZOL 5, OGM + AL 5 + RSV 10, OGM + ZOL 5 + RSV 10 | Proliferation and differentiation | MTT, ELISA, immunohistochemistry, Alizarin Red S staining | Protective role of CGF + resveratrol on osteoblasts treated with bisphosphonates |
| Yilmaz et al. (2018) | SaOS-2 osteoblast-like cells cultured on titanium discs | CGFe | Untreated control group | Cell counts, cell proliferation, OCN levels and ALP activity | MTT, ELISA | More proliferation and differentiation in CGF group |
| Jun et al. (2018) | Human dental pulp cells and HUVECs | CGF extracts (2, 5, 10, and 15%) | DMEM | Proliferation, migration, angiogenesis-associated mRNA and protein expression, angiogenic capacity | CCK-8 assay, cell cycle assay, Transwell assay, qRT-PCR, Western blotting, tube formation assay | More proliferation, differentiation, and migration in CGF groups in a dose-dependent manner |
| Chen, Jiao, et al. (2019) | NHDFs | Four concentrations of CCM: 5, 10, 15, and 20% | Normal, and cellular photoaging models | Cell viability, migration, amount of oxygen free radicals and antioxidative enzymes | MTT, ROS assay, SOD assay, scratch assay | Positive effect of CGF on scavenging ROS, improving SOD, and increasing migration rates of cells |
| Zhang and Ai (2019) | Rabbit PDCs | CGF membranes or CGF conditioned media | Untreated control group | Cell proliferation, osteogenic differentiation and angiogenic potential | CCK-8, ALP activity, immunohistochemistry, ELISA, qPCR, Western blot | Increased proliferation and osteogenic differentiation and angiogenic potential of PDCs treated with CGF |
| Tian et al. (2019) | DPCs | Different dose of CGF membrane | Untreated control group | Proliferation, migration, odontogenic differentiation | CCK-8, Transwell assay, Alizarin Red staining, alkaline phosphatase activity, Western blot and qPCR | Increase proliferation, migration and differentiation with application of CGF |
| Borsani et al. (2020) | Human SH-SY5Y neuronal cells | CGF or CGF+ retinoic acid | (1) Untreated control group and (2) differentiated control (supplemented with retinoic acid) | Cell proliferation, cell viability, cell differentiation | Automated cell counter; MTT assay; immunocytochemistry, Western blotting, ELISA | Decrease of cell proliferation and increase of cellular differentiation in the presence of CGF |

Abbreviations: AL, alendronate; ALP, alkaline phosphatase; CCK-8, cell counting kit-8; CCM, conditioned medium; A-PRF, advanced platelet-rich fibrin; CGF, concentrated growth factor; CGFe, CGF exudate; DMEM, Dulbecco's modified Eagle medium; DPCs, dental pulp cells; ELISA, enzyme-linked immunosorbent assay; FACS, flow cytometry; GDNF, glial cell-derived neurotrophic factor; HOB, human osteoblast; HUVECs, human umbilical vein endothelial cells; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NHDF, normal human dermal fibroblasts; NGF, nerve growth factor; OCN, osteocalcin; PDCs, periosteum-derived cells; PPP, platelet-poor plasma; PRGF, plasma rich in growth factors; PRP, platelet-rich plasma; qPCR, quantitative polymerase chain reaction; ROS, reactive oxygen species assay; RSV, resveratrol; SCs, Schwann cells; SAOS-2, sarcoma osteogenic; SOD, superoxide dismutase assay; ZOL, zoledronate or zoledronic acid.

**Table 4.**List of studies on the effects of CGF on bone regeneration

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author** | **Study** | **Intervention** | **Control group** | **Assays** | **Outcome** |
| Honda et al. (2013) | Animal study (*Rattus norvegicus* calvaria defect model) | CGF alone, CGF + BMSCs | Unfilled defect | Micro-CT and histological analysis | Completely repair of critical-size bone defects with CGF + BMSCs |
| Kim, Kim, Sandor, and Kim (2014) | Animal study (rabbit-skull defect) | CGF | PRP, PRF, and void | Micro-CT and histomorphometries | Similar effect of PRP, PRF, and CGF on bone formation |
| Takeda et al. (2015) | Animal study (rat calvaria bone defects) | CGF | PPP gel or left unfilled | Micro-CT and histological analysis | More bone formation in defects treated with CGF |
| Yang, Liu, Chen, Xie, and Wu (2015) | Human study (reducing bone resorption in immediate implant) | CGF | Bio-Oss | CBCT | No significant bone regeneration in using CGF alone |
| Durmuslar et al. (2016) | Animal study (healing of peri-implant bone defects in New Zealand white rabbits) | CGF, AB + CGF | Untreated defect, AB | Histomorphometrically | Best bone regeneration in CGF + AB |
| Park et al. (2016) | Animal study (femur defect in adult dogs) | CGF | Unfilled defect, PRF, synthetic bone | Histomorphometry evaluation, detection of TGF-b and VEGF, SEM | More bone formation in allograft group. Better results in CGF than PRF |
| Qiao et al. (2016) | Human study (intrabony defect treatment) | CGFs + BPBM | BPBM alone | Radiographic measurements | Improved clinical effectiveness in CGFs + BPBM |
| Pirpir et al. (2017) | Human study (implant placement) | CGF membrane in implant cavity walls, CGF fluid on the surfaces of implants | Conventional implant placement | RFA with the Osstell device | Positive effects of CGF on implant stabilization and osseointegration |
| Wang, Sun, He, and Wang (2017) | Animal study (maxillary sinus floor augmentation in beagle dogs) | CGFs/Bio-Oss (1:1) | BMSCs/Bio-Oss construct, or Bio-Oss alone | Micro-CT, microhardness test, histological examination, and histomorphometry | Increase bone formation in combination of Bio-Oss/CGFs |
| Shetty, Kalra, and Hegde (2018) | Human study (sinus elevation) | CGF | No graft material | CBCT | Higher bone densities and lower bone formation in CGF-treated group |
| Huang, Zou, He, Ouyang, and Piao (2018) | Human study (alveolar cleft) | Alveolar bone grafting combined with CGF | Acellular dermal matrix film combined with alveolar bone grafting using iliac crest bone grafts | CBCT | Improvement of bone density in CGF-treated groups |
| Chen et al. (2018) | Animal study (male Wistar rats with calvaria defects) | CGF + BMSCs; CGF | Collagen + BMSCs; collagen; blank | Micro-CT, histological and immunohistological analysis | Highest level of bone regeneration in CGF + BMSC group |
| Yilmaz et al. (2018) | Animal study (rabbit) | Masquelet technique + CGF | Masquelet technique as control groups | Histopathology and immunohistochemistry | Improvement of the quality of the membrane with addition of CGF to the Masquelet technique |
| Isler, Soysal, Ceyhanli, Bakirarar, and Unsal (2018) | Randomized clinical trial (peri-implantitis) | Bone substitute + CGF | Bone substitute + CM | Radiographic evaluation | Better results in collagen membrane + bone substitute |
| Lei et al. (2019) | Human study (retrospective cohort study for GTR | CGF + GTR | A-PRF + GTR, or GTR surgery | Radiographic evaluation, recording PD and CAL | No difference between A-PRF and CGF, more favorable clinical result in both groups than the control |
| Özveri Koyuncu, İçpınar Çelik, Özden Yüce, Günbay, and Çömlekoğlu (2019) | Human study (implant stability) | Dental implant socket covered with CGF membrane | Conventionally prepared socket | Implant stability measured by RFA | Not significant difference between groups |
| Xu, Qiu, et al. (2019) | Human study (implant stability) | Flap surgery + CGF (a), flap surgery + CGF + Bio-Oss (b) | Flap surgery alone (c), flap surgery + Bio-Oss (d) | Recording PD and CAL change | No significant difference between Groups b and d |
| Kizilaslan, Karabuda, and Olgac (2020) | Diabetic rat model (calvaria defects) | (1) Empty bone defect, (2) xenogenous graft, (3) CGF, (4) CGF + xenogenous graft | Healthy control group | Histomorphometric analysis | Highest rate of bone healing in CGF + xenogenous graft group |

Abbreviations: AB, autogenous bone; A-PRF, advanced platelet-rich fibrin; BMSCs, bone mesenchymal stem cells; BPBM, bovine porous bone mineral; CAL, clinical attachment level; CBCT, cone beam computed tomography; CGF, concentrated growth factor; CM, collagen membrane; GTR, guided tissue regeneration; micro-CT, microcomputed tomography; PD, probing depth; PPP, platelet-poor plasma; PRP, platelet-rich plasma; RFA, resonance frequency analysis; SEM, scanning electron microscope; TGF-β, transforming growth factor beta; VEGF, vascular endothelial growth factor.

**Table 5.**List of studies on the effects of CGF on regeneration of other tissues than bone

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author** | **Study** | **Tissue or disorder** | **Intervention** | **Control group** | **Assays** | **Outcome** |
| Bozkurt Dogan, Ongoz Dede, Balli, Atalay, and Durmuslar (2015) | Split-mouth randomized clinical trial | Multiple adjacent GRs | CGF membrane + CAF | CAF alone | CRC, MRC, RD, PD, RW, CAL, KGW, GT, GR depth, PD | Did not provide additional benefits in RD, CRC and MRC by using CGF + CAF, but significant increase in KGW and GT |
| Qin, Wang, Sun, et al. (2016) | Animal study (rat model) | Sciatic nerve crush injury | CGF membrane | Blank control | Functional nerve recovery using an SFI | Increase of the sciatic functional index by CGF |
| Topkara, Ozkan, Ozcan, Oksuz, and Akbulut (2016) | Animal study (New Zealand white rabbits) | Diced cartilage grafts | Diced cartilage wrapped with CGF | Bare diced cartilage; diced cartilage wrapped with fascia; diced cartilage wrapped with fenestrated fascia; diced cartilage wrapped with blood glue | HE staining, Masson's trichrome, Toluidine blue, Safranin-O staining, immunohistochemical staining of GFAP | Improvement of the viability of diced cartilage grafts by CGF |
| Wang et al. (2017) | Animal study (goat) | TMJ-OA | CGF membrane | Physiologic saline was applied to the left joints (unrepaired group) | Histopathologic observations with HE | Tissue repair and regeneration in CGF-repaired condyle |
| Hu et al. (2018) | Animal study (nude mice) | Fat graft | 1 ml of CGF | 1 ml of PRP, PRF | H&E and immunohistochemical analysis | More normal adipocytes and fewer fat vacuoles in the CGF group |
| Xu, Qiao, et al. (2019) | Beagle dogs | Immature teeth | CGF used as root canal filling agent | Positive control (no treatment), negative control (only root canal preparing) | Radiography, H&E, Masson trichrome technique, immunohistochemical analysis | Dentine-pulp complex regeneration in the immature teeth in the presence of CGF |

Abbreviations: CAF, coronally advanced flap; CAL, clinical attachment level; CGF, concentrated growth factor; CRC, complete root coverage; GFAP, glial fibrillary acidic protein; GRs, gingival recessions; GT, gingival thickness; H&E, hematoxylin and eosin; KGW, keratinized gingiva width; MRC, mean root coverage; PD, probing pocket depth; PRF, platelet rich fibrin; PRP, platelet-rich plasma; RD, recession depth; RW, recession width; SFI, sciatic functional index; TMJ-OA, temporomandibular joint osteoarthritis.

## 3.3 Effect of CGF on adult cells or cell line

Adult cells or cell lines used for assessment of CGF are NHDF, HUVEC, HOB, Rat bone marrow cells, Schwann cells, SaOS-2, periosteal cells, and dental pulp cells (Table **3**). Positive effects of CGF on proliferation, migration, and differentiation were reported in these studies; however, Borsani et al. reported the decrease of cell proliferation and increase of cellular differentiation in the presence of CGF (Borsani et al., **2020**). Only one study in this group compared CGF extract with other platelet concentrate including PRP, PRGF, and A-PRF extract and reported more proliferation in PRP-treated cells (Masuki et al., **2016**). While in the study of Jun et al. on CGF extracts (2, 5, 10, and 15%), a dose-dependent manner in CGF groups was reported, study of Chen et al. on the effects of 5, 10, 15, and 20% concentrations of CCM showed better effect of 5% CGF in comparison to other concentrations (Chen, Jiao, et al., **2019**; Jun et al., **2018**).

## 3.4 In vivo effect of CGF

Since the introduction of CGF by Sacco in 2006, many studies have evaluated the osteoinductive and regenerative properties of CGF in clinical studies as case series, animal studies, or clinical trials. In this regard, with excluding case series (without a control group), 18 studies on bone regeneration and six studies on regeneration of other tissues are listed in Tables **4** and **5**. Two articles were randomized clinical trials and one was a cohort study in which the treated pathologies were peri-implantitis, guided tissue regeneration (GTR), and gingival recessions (Bozkurt Dogan et al., **2015**; Isler et al., **2018**; Lei et al., **2019**). Most studies stated improvement of tissue healing or regeneration in the presence of CGF, yet three studies investigating its effect on peri-implantitis, implant stability, and immediate implants reported no significant difference or lower effect of CGF (Isler et al., **2018**; Özveri Koyuncu, İçpınar Çelik, et al., **2019**; Yang et al., **2015**). Combination of CGF with stem cells or grafts resulted in better results than CGF alone (Chen et al., **2018**; Durmuslar et al., **2016**; Honda et al., **2013**; Kizilaslan et al., **2020**; Qiao et al., **2016**; Wang et al., **2017**). Three studies compared CGF to other platelets concentrates; one study reported no significant difference between CGF, PRP, and PRF on bone formation in rabbit-skull defect (Kim et al., **2014**), another study also confirmed no significant difference in GTR between A-PRF and CGF (Lei et al., **2019**); while Park et al. indicated better bone formation of CGF than PRF in femur defect of adult dogs (Park et al., **2016**).

# 4 DISCUSSION

The aim of the present study was to summarize the biological effects of CGF. Stem cells and primary cells (which are taken directly from tissues) or continuously grown cells/cell lines are commonly used in in vitro studies. The similarity of the characteristics of primary cells to in vivo conditions makes them a good candidate for cell culture experiments. However, continuous cell lines, due to their genetic stability, are better for the standardization of in vitro assays (Kaur & Dufour, **2012**).

As seen in the result of this review, CGF was used alone in in vitro studies, but in in vivo studies, the combination of CGF with stem cells or biomaterials has been reported (Chen et al., **2018**; Durmuslar et al., **2016**; Masuki et al., **2016**; Qiao et al., **2016**; Qiao & An, **2017**; Rodella et al., **2011**). Tissue engineering is a complex of stem cells, scaffold, and growth factors. Fiber network in CGF can play a role as bioscaffold by securing growth factors in its fibrin fibers (Kobayashi et al., **2012**); however, its combination with another scaffold could change the dynamic of growth factor release. Architecture and components of different scaffolds may provide more interface area for release or affect its cell attachment (Yu et al., **2019**). Bonazza et al. showed that the mixture of CGFs with β-TCP could increase the release of BMP-2 and BMP-7 due to the presence of Ca ions in β-TCP (Bonazza et al., **2018**).

Cell migration, adhesion, proliferation, differentiation, and angiogenesis are the sequential events in regeneration; various growth factors in CGF, along with its 3D network structure, can induce these events (Rodella et al., **2011**). Most studies listed in Tables **2** and **3** have focused on proliferation and osteogenic differentiation. However, the effects of CGF on migration and endothelial differentiation or angiogenesis were also under investigation in four studies included in this review (Hong et al., **2019**; Jin et al., **2018**; Jun et al., **2018**; Qin, Wang, Sun, et al., **2016**). Improvement of cell migration is the result of a high concentration of chemotactic factors, such as PDGF-BB and bFGF in CGF. The effects of PDGF-BB and bFGF on cell homing have been reported in previous studies (Takeuchi et al., **2015**; Zhang et al., **2017**). TGF and IGF-I have also been shown to facilitate the migration of cells (Maucksch et al., **2013**; Takai et al., **2012**). On the other hand, the presence of CD34 positive cells in CGF explains its angiogenesis feature (Kikuchi-Taura, Soma, Matsuyama, Stern, & Taguchi, **2006**). Also, migration of endothelial cells can be stimulated by VEGF content of CGF (Morales-Ruiz et al., **2000**).

There were some controversies in reporting the optimal concentration of CGF in different studies. Some studies reported the positive effect of CGF on proliferation in a dose-dependent manner, but such results were not reported in all studies (Hong et al., **2019**). This could be related to the non-standardization of platelet count in CGF, which may affect the pH value of the medium. Change in pH value by platelet concentrates disturbs cell proliferation (Liu, Kalen, Risto, & Wahlstrom, **2002**). Also, different concentrations of CGF among the donors, different blood volumes used for CGF preparation, and different periods used for preparing CGF extract could disturb the results. Another agent is the test tube used for blood collection, which its material may interfere with the properties of CGF (Bonazza et al., **2016**; Tsujino et al., **2019**). The release dynamics of growth factors should be considered before obtaining the extract. Although Borsani et al. assumed that release of growth factors from CGF continue for almost 8 days (Borsani et al., **2015**), more sophistical research showed that some of the growth factors are released during 8 hr, while the release of some others continues throughout 13 days (Dohan Ehrenfest, de Peppo, Doglioli, & Sammartino, **2009**; Honda et al., **2013**; Zumstein et al., **2012**). Based on these differences, the optimum concentration of CGF could vary in studies.

Most studies have focused on the osteogenic differentiation effect of CGF. Two studies have evaluated odontoblastic differentiation under treatment with CGF (Hong et al., **2019**; Jin et al., **2018**), and two others, neuropathic differentiation (Qin, Wang, Sun, et al., **2016**; Qin, Wang, Zheng, et al., **2016**). It should be noted that differentiation is related to growth factors as well as inflammatory cytokines, which might have synergistic or antagonistic effects in CGF (Liu et al., **2016**).

The result of animal and human studies demonstrates that, presently, most studies are about the effectiveness of CGF in bone regeneration. Applications of CGF in filling extraction sockets, sinus lift procedure, ridge augmentation surgeries, gingival recession, mixture with autologous bone or biomaterials, or application in implants as a membrane or liquid coating are the most common reports in bone regeneration (Table **4**). In most of the cases, the improvement of bone repair in the presence of CGF was demonstrated. The comparison between CGF alone and the combination of CGF with stem cells show the highest regeneration in their combination. Also, the results in this review highlight the fact that the combination of CGF and biomaterials like BPBM, Bio-Oss or other bone substitute improve tissue regeneration. Only one study reported the mixing ratio (1:1) (Wang et al., **2017**). The optimal mixing ratio should be clarified in future studies.

Common assays for evaluating the result of in vivo studies were micro-CT or CBCT, histological and immunohistological staining. Additionally, six studies have shown that CGF is beneficial in the treatment of other tissues like nerve injury, cartilage, TMJ, and fat graft (Table **5**).

One of the limitations of research on platelet derivatives is the nonstandard process of collecting blood, which could influence the resulting outcome. Consequently, a distinct prospect for evidence-based dentistry is the standardization of the CGF preparation methods, consideration of intraindividual differences and comparison of in vitro and in vivo studies. Meanwhile, considering all the beneficial effects of CGF, awareness of dental practitioner about this natural biomaterial and its advantages should be improved (Prakash, Ganapathy, & Mallikarjuna, **2019**).

# 5 CONCLUSION

Overview of 45 articles, regarding the in vivo and in vitro studies on CGF, reveals the beneficial effects of CGF as a natural scaffold and reservoir of growth factors in regenerative medicine. The material of test tube used for blood collection, different concentrations of CGF among the donors, different blood volumes used for CGF preparation, platelet count in CGF, different periods used for preparing CGF extract, and different types of CGF used for application (fresh, freeze-dried, extract, exudate, membrane) could explain different results in reporting better effects of CGF than PRF or no significant difference between them. More well-designed studies could help in standardization of CGF protocols.

# REFERENCES

Agrawal, A. A. (2017). Evolution, current status and advances in application of platelet concentrate in periodontics and implantology. *World Journal of Clinical Cases*, **5**(5), 159– 171.

Bakhtiar, H., Esmaeili, S., Fakhr Tabatabayi, S., Ellini, M. R., Nekoofar, M. H., & Dummer, P. M. (2017). Second-generation platelet concentrate (platelet-rich fibrin) as a scaffold in regenerative endodontics: A case series. *Journal of Endodontia*, **43**(3), 401– 408.

Beitzel, K., Allen, D., Apostolakos, J., Russell, R. P., McCarthy, M. B., Gallo, G. J., … Mazzocca, A. D. (2015). US definitions, current use, and FDA stance on use of platelet-rich plasma in sports medicine. *The Journal of Knee Surgery*, **28**(1), 29– 34.

Bonazza, V., Borsani, E., Buffoli, B., Castrezzati, S., Rezzani, R., & Rodella, L. F. (2016). How the different material and shape of the blood collection tube influences the concentrated growth factors production. *Microscopy Research and Technique*, **79**(12), 1173– 1178.

Bonazza, V., Hajistilly, C., Patel, D., Patel, J., Woo, R., Cocchi, M. A., et al. (2018). Growth factors release from concentrated growth factors: Effect of beta-Tricalcium phosphate addition. *The Journal of Craniofacial Surgery*, **29**(8), 2291– 2295.

Borsani, E., Bonazza, V., Buffoli, B., Cocchi, M. A., Castrezzati, S., Scarì, G., … Parolini, S. (2015). Biological characterization and in vitro effects of human concentrated growth factor preparation: An innovative approach to tissue regeneration. *Biologie et Médecine*, **7**(5), 726.

Borsani, E., Bonazza, V., Buffoli, B., Nocini, P. F., Albanese, M., Zotti, F., … Rodella, L. F. (2018). Beneficial effects of concentrated growth factors and resveratrol on human osteoblasts in vitro treated with bisphosphonates. *BioMed Research International*, **2018**, 4597321.

Borsani, E., Buffoli, B., Bonazza, V., Brunelli, G., Monini, L., Inchingolo, F., … Rodella, L. (2020). In vitro effects of concentrated growth factors (CGF) on human SH-SY5Y neuronal cells. *European Review for Medical and Pharmacological Sciences*, **24**, 304– 314.

Bozkurt Dogan, S., Ongoz Dede, F., Balli, U., Atalay, E. N., & Durmuslar, M. C. (2015). Concentrated growth factor in the treatment of adjacent multiple gingival recessions: A split-mouth randomized clinical trial. *Journal of Clinical Periodontology*, **42**(9), 868– 875.

Brignardello-Petersen, R. (2020). Concentrated growth factor seems to have benefits in outcomes after extraction of partially impacted third molars. *Journal of the American Dental Association (1939)*.

Chen, J., Jiao, D., Zhang, M., Zhong, S., Zhang, T., Ren, X., & Ren, G. (2019). Concentrated growth factors can inhibit photoaging damage induced by ultraviolet A (UVA) on the human dermal fibroblasts in vitro. *Medical Science Monitor*, **25**, 3739– 3749.

Chen, X., Chen, Y., Hou, Y., Song, P., Zhou, M., Nie, M., & Liu, X. (2019). Modulation of proliferation and differentiation of gingiva derived mesenchymal stem cells by concentrated growth factors: Potential implications in tissue engineering for dental regeneration and repair. *International Journal of Molecular Medicine*, **44**(1), 37– 46.

Chen, X., Wang, J., Yu, L., Zhou, J., Zheng, D., & Zhang, B. (2018). Effect of concentrated growth factor (CGF) on the promotion of osteogenesis in bone marrow stromal cells (BMSC) in vivo. *Scientific Reports*, **8**(1), 5876.

Doan, N., Reher, P., Duong, Q. T., Wang, G., & Truong, L. (2019). Application of blood stem cells (CD34+ and CD45)/concentrated growth factors (CGF) in guided bone regeneration (GBR) and guided tissue regeneration (GTR) in conjunction with MLS laser and piezoelectric surgery. *International Journal of Oral and Maxillofacial Surgery*, **48**, 62.

Dohan Ehrenfest, D. M., Andia, I., Zumstein, M. A., Zhang, C.-Q., Pinto, N. R., & Bielecki, T. (2014). Classification of platelet concentrates (platelet-rich plasma-PRP, platelet-rich fibrin-PRF) for topical and infiltrative use in orthopedic and sports medicine: Current consensus, clinical implications and perspectives. *Muscles, Ligaments and Tendons Journal*, **4**(1), 3– 9.

Dohan Ehrenfest, D. M., de Peppo, G. M., Doglioli, P., & Sammartino, G. (2009). Slow release of growth factors and thrombospondin-1 in Choukroun's platelet-rich fibrin (PRF): A gold standard to achieve for all surgical platelet concentrates technologies. *Growth Factors*, **27**(1), 63– 69.

Durmuslar, M. C., Balli, U., Dede, F. O., Misir, A. F., Baris, E., Kurkcu, M., & Kahraman, S. A. (2016). Histological evaluation of the effect of concentrated growth factor on bone healing. *The Journal of Craniofacial Surgery*, **27**(6), 1494– 1497.

Honda, H., Tamai, N., Naka, N., Yoshikawa, H., & Myoui, A. (2013). Bone tissue engineering with bone marrow-derived stromal cells integrated with concentrated growth factor in *Rattus norvegicus* calvaria defect model. *Journal of Artificial Organs*, **16**(3), 305– 315.

Hong, S., Chen, W., & Jiang, B. (2018). A comparative evaluation of concentrated growth factor and platelet-rich fibrin on the proliferation, migration, and differentiation of human stem cells of the apical papilla. *Journal of Endodontia*, **44**(6), 977– 983.

Hong, S., Li, L., Cai, W., & Jiang, B. (2019). The potential application of concentrated growth factor in regenerative endodontics. *International Endodontic Journal*, **52**(5), 646– 655.

Hu, Y., Jiang, Y., Wang, M., Tian, W., & Wang, H. (2018). Concentrated growth factor enhanced fat graft survival: A comparative study. *Dermatologic Surgery*, **44**(7), 976– 984.

Huang, L., Zou, R., He, J., Ouyang, K., & Piao, Z. (2018). Comparing osteogenic effects between concentrated growth factors and the acellular dermal matrix. *Brazilian Oral Research*, **32**, e29.

Isler, S. C., Soysal, F., Ceyhanli, T., Bakirarar, B., & Unsal, B. (2018). Regenerative surgical treatment of peri-implantitis using either a collagen membrane or concentrated growth factor: A 12-month randomized clinical trial. *Clinical Implant Dentistry and Related Research*, **20**(5), 703– 712.

Jin, R., Song, G., Chai, J., Gou, X., Yuan, G., & Chen, Z. (2018). Effects of concentrated growth factor on proliferation, migration, and differentiation of human dental pulp stem cells in vitro. *Journal of Tissue Engineering*, **9**, 2041731418817505.

Jones, I. A., Togashi, R. C., & Thomas Vangsness, C., Jr. (2018). The economics and regulation of PRP in the evolving field of orthopedic biologics. *Current Reviews in Musculoskeletal Medicine*, **11**(4), 558– 565.

Jun, H., Lei, D., Qifang, Y., Yuan, X., & Deqin, Y. (2018). Effects of concentrated growth factors on the angiogenic properties of dental pulp cells and endothelial cells: An in vitro study. *Brazilian Oral Research*, **32**, e48.

Kang, Y. H., Jeon, S. H., Park, J. Y., Chung, J. H., Choung, Y. H., Choung, H. W., … Choung, P. H. (2011). Platelet-rich fibrin is a bioscaffold and reservoir of growth factors for tissue regeneration. *Tissue Engineering. Part A*, **17**(3–4), 349– 359.

Kaur, G., & Dufour, J. M. (2012). Cell lines: Valuable tools or useless artifacts. *Spermatogenesis*, **2**(1), 1– 5.

Kikuchi-Taura, A., Soma, T., Matsuyama, T., Stern, D. M., & Taguchi, A. (2006). A new protocol for quantifying CD34(+) cells in peripheral blood of patients with cardiovascular disease. *Texas Heart Institute Journal*, **33**(4), 427– 429.

Kim, T. H., Kim, S. H., Sandor, G. K., & Kim, Y. D. (2014). Comparison of platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in rabbit-skull defect healing. *Archives of Oral Biology*, **59**(5), 550– 558.

Kizilaslan, S., Karabuda, Z. C., & Olgac, V. (2020). The effect of concentrated growth factor on calvarial bone in diabetic healing. *The Journal of Craniofacial Surgery*, **31**(1), 158– 161.

Kobayashi, M., Kawase, T., Horimizu, M., Okuda, K., Wolff, L. F., & Yoshie, H. (2012). A proposed protocol for the standardized preparation of PRF membranes for clinical use. *Biologicals*, **40**(5), 323– 329.

Kusuma, G. D., Carthew, J., Lim, R., & Frith, J. E. (2017). Effect of the microenvironment on mesenchymal stem cell paracrine signaling: Opportunities to engineer the therapeutic effect. *Stem Cells and Development*, **26**(9), 617– 631.

Lei, L., Yu, Y., Han, J., Shi, D., Sun, W., Zhang, D., & Chen, L. (2019). Quantification of growth factors in advanced platelet-rich fibrin and concentrated growth factors and their clinical efficiency as adjunctive to the GTR procedure in periodontal intrabony defects. *Journal of Periodontology*. [Epub ahead of print]

Li, X., Yang, H., Zhang, Z., Yan, Z., Lv, H., Zhang, Y., & Wu, B. (2019). Concentrated growth factor exudate enhances the proliferation of human periodontal ligament cells in the presence of TNFalpha. *Molecular Medicine Reports*, **19**(2), 943– 950.

Liu, C., Xiong, H., Chen, K., Huang, Y., Huang, Y., & Yin, X. (2016). Long-term exposure to pro-inflammatory cytokines inhibits the osteogenic/dentinogenic differentiation of stem cells from the apical papilla. *International Endodontic Journal*, **49**(10), 950– 959.

Liu, Y., Kalen, A., Risto, O., & Wahlstrom, O. (2002). Fibroblast proliferation due to exposure to a platelet concentrate in vitro is pH dependent. *Wound Repair and Regeneration*, **10**(5), 336– 340.

Lundquist, R., Dziegiel, M. H., & Agren, M. S. (2008). Bioactivity and stability of endogenous fibrogenic factors in platelet-rich fibrin. *Wound Repair and Regeneration*, **16**(3), 356– 363.

Masuki, H., Okudera, T., Watanebe, T., Suzuki, M., Nishiyama, K., Okudera, H., … Kawase, T. (2016). Growth factor and pro-inflammatory cytokine contents in platelet-rich plasma (PRP), plasma rich in growth factors (PRGF), advanced platelet-rich fibrin (A-PRF), and concentrated growth factors (CGF). *International Journal of Implant Dentistry*, **2**(1), 19.

Maucksch, C., McGregor, A. L., Yang, M., Gordon, R. J., Yang, M., & Connor, B. (2013). IGF-I redirects doublecortin-positive cell migration in the normal adult rat brain. *Neuroscience*, **241**, 106– 115.

Mirkovic, S., Djurdjevic-Mirkovic, T., & Pugkar, T. (2015). Application of concentrated growth factors in reconstruction of bone defects after removal of large jaw cysts—The two cases report. *Vojnosanitetski Pregled*, **72**(4), 368– 371.

Mitchell, A. C., Briquez, P. S., Hubbell, J. A., & Cochran, J. R. (2016). Engineering growth factors for regenerative medicine applications. *Acta Biomaterialia*, **30**, 1– 12.

Morales-Ruiz, M., Fulton, D., Sowa, G., Languino, L. R., Fujio, Y., Walsh, K., & Sessa, W. C. (2000). Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. *Circulation Research*, **86**(8), 892– 896.

Nyberg, E., Holmes, C., Witham, T., & Grayson, W. L. (2016). Growth factor-eluting technologies for bone tissue engineering. *Drug Delivery and Translational Research*, **6**(2), 184– 194.

Özveri Koyuncu, B., İçpınar Çelik, K., Özden Yüce, M., Günbay, T., & Çömlekoğlu, M. E. (2019). The role of concentrated growth factor on implant stability: A preliminary study. *Journal of Stomatology, Oral and Maxillofacial Surgery*, **1**, 1– 5.

Özveri Koyuncu, B., Işık, G., Özden Yüce, M., Günbay, S., & Günbay, T. (2019). Effect of concentrated growth factor (CGF) on short-term clinical outcomes after partially impacted mandibular third molar surgery: A split-mouth randomized clinical study. *Journal of Stomatology, Oral and Maxillofacial Surgery*. [Epub ahead of print]

Park, H. C., Kim, S. G., Oh, J. S., You, J. S., Kim, J. S., Lim, S. C., et al. (2016). Early bone formation at a femur defect using CGF and PRF grafts in adult dogs: A comparative study. *Implant Dentistry*, **25**(3), 387– 393.

Phinney, D. G., & Pittenger, M. F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. *Stem Cells*, **35**(4), 851– 858.

Pirpir, C., Yilmaz, O., Candirli, C., & Balaban, E. (2017). Evaluation of effectiveness of concentrated growth factor on osseointegration. *International Journal of Implant Dentistry*, **3**(1), 7.

Prakash, M. S., Ganapathy, D. M., & Mallikarjuna, A. V. (2019). Knowledge awareness practice survey on awareness of concentrated growth factor among dentists. *Drug Invention Today*, **11**(3), 730– 733.

Qiao, J., & An, N. (2017). Effect of concentrated growth factors on function and Wnt3a expression of human periodontal ligament cells in vitro. *Platelets*, **28**(3), 281– 286.

Qiao, J., Duan, J., Zhang, Y., Chu, Y., & Sun, C. (2016). The effect of concentrated growth factors in the treatment of periodontal intrabony defects. *Future Science OA*, **2**(4), FS136.

Qin, J., Wang, L., Sun, Y., Sun, X., Wen, C., Shahmoradi, M., & Zhou, Y. (2016). Concentrated growth factor increases Schwann cell proliferation and neurotrophic factor secretion and promotes functional nerve recovery in vivo. *International Journal of Molecular Medicine*, **37**(2), 493– 500.

Qin, J., Wang, L., Zheng, L., Zhou, X., Zhang, Y., Yang, T., & Zhou, Y. (2016). Concentrated growth factor promotes Schwann cell migration partly through the integrin beta1-mediated activation of the focal adhesion kinase pathway. *International Journal of Molecular Medicine*, **37**(5), 1363– 1370.

Raghoebar, G. M., Schortinghuis, J., Liem, R. S., Ruben, J. L., van der Wal, J. E., & Vissink, A. (2005). Does platelet-rich plasma promote remodeling of autologous bone grafts used for augmentation of the maxillary sinus floor? *Clinical Oral Implants Research*, **16**(3), 349– 356.

Rodella, L. F., Favero, G., Boninsegna, R., Buffoli, B., Labanca, M., Scari, G., … Rezzani, R. (2011). Growth factors, CD34 positive cells, and fibrin network analysis in concentrated growth factors fraction. *Microscopy Research and Technique*, **74**(8), 772– 777.

Shetty, M., Kalra, R., & Hegde, C. (2018). Maxillary sinus augmentation with concentrated growth factors: Radiographic evaluation. *Journal of Osseointegration*, **10**(4), 109– 114.

Shyu, S. S., Fu, E., & Shen, E. C. (2016). Clinical and microcomputed topography evaluation of the concentrated growth factors as a sole material in a cystic bony defect in alveolar bone followed by dental implantation: A case report. *Implant Dentistry*, **25**(5), 707– 714.

Sohn, D. S., Heo, J. U., Kwak, D. H., Kim, D. E., Kim, J. M., Moon, J. W., … Park, I. S. (2011). Bone regeneration in the maxillary sinus using an autologous fibrin-rich block with concentrated growth factors alone. *Implant Dentistry*, **20**(5), 389– 395.

Takai, E., Tsukimoto, M., Harada, H., Sawada, K., Moriyama, Y., & Kojima, S. (2012). Autocrine regulation of TGF-beta1-induced cell migration by exocytosis of ATP and activation of P2 receptors in human lung cancer cells. *Journal of Cell Science*, **125**(Pt 21), 5051– 5060.

Takeda, Y., Katsutoshi, K., Matsuzaka, K., & Inoue, T. (2015). The effect of concentrated growth factor on rat bone marrow cells in vitro and on calvarial bone healing in vivo. *The International Journal of Oral & Maxillofacial Implants*, **30**(5), 1187– 1196.

Takeuchi, N., Hayashi, Y., Murakami, M., Alvarez, F. J., Horibe, H., Iohara, K., … Nakashima, M. (2015). Similar in vitro effects and pulp regeneration in ectopic tooth transplantation by basic fibroblast growth factor and granulocyte-colony stimulating factor. *Oral Diseases*, **21**(1), 113– 122.

Tatullo, M., Codispoti, B., Paduano, F., Nuzzolese, M., & Makeeva, I. (2019). Strategic tools in regenerative and translational dentistry. *International Journal of Molecular Sciences*, **20**(8), E1879.

Thomas, D., Gaspar, D., Sorushanova, A., Milcovich, G., Spanoudes, K., Mullen, A. M., … Zeugolis, D. I. (2016). Scaffold and scaffold-free self-assembled systems in regenerative medicine. *Biotechnology and Bioengineering*, **113**(6), 1155– 1163.

Tian, S., Wang, J., Dong, F., Du, N., Li, W., Song, P., & Liu, Y. (2019). Concentrated growth factor promotes dental pulp cells proliferation and mineralization and facilitates recovery of dental pulp tissue. *Medical Science Monitor*, **25**, 10016– 10028.

Topkara, A., Ozkan, A., Ozcan, R. H., Oksuz, M., & Akbulut, M. (2016). Effect of concentrated growth factor on survival of diced cartilage graft. *Aesthetic Surgery Journal*, **36**(10), 1176– 1187.

Tsujino, T., Masuki, H., Nakamura, M., Isobe, K., Kawabata, H., Aizawa, H., et al. (2019). Striking differences in platelet distribution between advanced-platelet-rich fibrin and concentrated growth factors: Effects of silica-containing plastic tubes. *Journal of Functional Biomaterials*, **10**(3), 43.

Wang, F., Sun, Y., He, D., & Wang, L. (2017). Effect of concentrated growth factors on the repair of the goat temporomandibular joint. *Journal of Oral and Maxillofacial Surgery*, **75**(3), 498– 507.

Xu, F., Qiao, L., Zhao, Y., Chen, W., Hong, S., Pan, J., & Jiang, B. (2019). The potential application of concentrated growth factor in pulp regeneration: An in vitro and in vivo study. *Stem Cell Research & Therapy*, **10**(1), 134.

Xu, Y., Qiu, J., Sun, Q., Yan, S., Wang, W., Yang, P., & Song, A. (2019). One-year results evaluating the effects of concentrated growth factors on the healing of intrabony defects treated with or without bone substitute in chronic periodontitis. *Medical Science Monitor*, **25**, 4384– 4389.

Yang, L. M., Liu, Z. Z., Chen, S. P., Xie, C., & Wu, B. (2015). The study of the effect of concentrated growth factors (CGF) on the new bone regeneration of immediate implant. *Advanced Materials Research*, **1088**, 500– 502.

Yilmaz, O., Ozmeric, A., Alemdaroglu, K. B., Celepli, P., Hucumenoglu, S., & Sahin, O. (2018). Effects of concentrated growth factors (CGF) on the quality of the induced membrane in Masquelet's technique—An experimental study in rabbits. *Injury*, **49**(8), 1497– 1503.

Yu, B., & Wang, Z. (2014). Effect of concentrated growth factors on beagle periodontal ligament stem cells in vitro. *Molecular Medicine Reports*, **9**(1), 235– 242.

Yu, M., Wang, X., Liu, Y., & Qiao, J. (2019). Cytokine release kinetics of concentrated growth factors in different scaffolds. *Clinical Oral Investigations*, **23**(4), 1663– 1671.

Zhang, L., & Ai, H. (2019). Concentrated growth factor promotes proliferation, osteogenic differentiation, and angiogenic potential of rabbit periosteum-derived cells in vitro. *Journal of Orthopaedic Surgery and Research*, **14**(1), 146.

Zhang, M., Jiang, F., Zhang, X., Wang, S., Jin, Y., Zhang, W., & Jiang, X. (2017). The effects of platelet-derived growth factor-BB on human dental pulp stem cells mediated dentin-pulp complex regeneration. *Stem Cells Translational Medicine*, **6**(12), 2126– 2134.

Zumstein, M. A., Berger, S., Schober, M., Boileau, P., Nyffeler, R. W., Horn, M., & Dahinden, C. A. (2012). Leukocyte- and platelet-rich fibrin (L-PRF) for long-term delivery of growth factor in rotator cuff repair: Review, preliminary results and future directions. *Current Pharmaceutical Biotechnology*, **13**(7), 1196– 1206.